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S U M M A R Y
Objective: Invasive pulmonary aspergillosis (IPA) and Pneumocystis pneumonia (PCP) are two types of
pulmonary fungal infection that are not easy to differentiate. The purpose of this study was to investigate
the role of inﬂammatory cytokines in the differential diagnosis of IPA and PCP.
Methods: A total of 227 pediatric oncology patients diagnosed with acute pneumonia were enrolled.
They were divided into three groups: IPA, PCP, and ‘others’. The cytokine levels in these groups were
compared, including interferon (IFN)-g, tumor necrosis factor (TNF)-a, interleukin (IL)-10, IL-6, IL-4, and
IL-2.
Results: Of the six cytokines, only IL-6 and IFN-g levels were elevated in patients with acute pneumonia.
IL-6 was comparable between patients with IPA and PCP (52.0 pg/ml vs. 25.8 pg/ml, p = 0.092), while IFN-
g was much higher in patients with PCP (19.9 pg/ml vs. 8.9 pg/ml, p = 0.001). The accuracy of IL-6 and the
ratio of IL-6/IFN-g in predicting IPA were 69.0% and 72.0%, respectively, while the accuracy of IFN-g to
predict PCP was 67.2%. IL-6 >140 pg/ml and IL-6/IFN-g >9.0 presented speciﬁcities of 90% in predicting
IPA, while IFN-g >40 pg/ml presented speciﬁcity of 90% in predicting PCP.
Conclusions: IL-6 is predominantly elevated in IPA, while IFN-g is signiﬁcantly increased in PCP. These
are helpful tools for the differential diagnosis of IPA and PCP.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Pulmonary infection is a common cause of mortality among
pediatric oncology patients, especially those with neutropenia.
Fungi are common pathogens, with an increasing morbidity and
high mortality.1 For example, patients with hematological
malignancies are the population most frequently affected by
invasive aspergillosis,2 and aspergillosis is the most common
fungal infection in children, accounting for about 75% of invasive
fungal disease.3 Pneumocystis jirovecii is a ubiquitous fungus that
can cause signiﬁcant respiratory disease in immunocompromised
hosts, with a mortality rate of 35–55% in HIV-negative patients.4
Both of these fungi are common in pediatric oncology patients after
intensive chemotherapy. However, due to the non-speciﬁc clinical
manifestations and the poor sensitivity or speciﬁcity of most* Corresponding authors. Tel.: +86 (571) 88873637; fax: +86 (571) 87033296.
E-mail addresses: y_m_tang@zju.edu.cn (Y.-M. Tang),
medico-xxj@163.com (X.-J. Xu).
1 Tel.: +86 (571) 88873450; fax: +86 (571) 87033296.
http://dx.doi.org/10.1016/j.ijid.2016.05.016
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).conventional laboratory tests and radiological imaging, the
diagnosis is often difﬁcult and delayed.5,6
Although these organisms can be identiﬁed using light
microscopy, immunoﬂuorescence, or molecular methods,7 it is
often difﬁcult to obtain the necessary samples from these patients,
such as bronchoalveolar lavage ﬂuid, induced sputum, and lung
biopsy specimens.8,9 Recently, Samuel et al. reported that the PCR
results for Pneumocystis pneumonia (PCP) using upper respiratory
samples presented high consistency with those obtained using
lower respiratory samples in children, which may make the
diagnosis of PCP easier.10 However, wider implementation of PCR
on upper respiratory samples for the diagnosis of PCP is warranted
to conﬁrm its accuracy.
Inﬂammatory cytokines including interleukin (IL)-6, IL-10,
tumor necrosis factor (TNF), and interferon (IFN)-g are important
biomarkers for distinguishing infections caused by various
pathogens. A prospective study was previously conducted on
the role of rapid cytokine proﬁle determination by ﬂow cytometry
in pediatric hematology–oncology patients who had experienced a
febrile illness since 2005. Previous studies have shown that theseciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Gram-negative bacteremia, viral and bacterial infections.11,12 In
order to investigate the role of inﬂammatory cytokines in
differentiating pulmonary infections caused by Aspergillus and
P. jirovecii, the clinical data of patients diagnosed with invasive
pulmonary aspergillosis (IPA) and PCP were collected retrospec-
tively and the cytokine proﬁles of the two entities were compared.
2. Patients and methods
2.1. Data collection
From January 2011 through June 2015, patients in the
Department of Hematology–Oncology of the Children’s Hospital
of Zhejiang University School of Medicine diagnosed with acute
pneumonia and with positive microbiological results were
enrolled. The patients were divided into three groups according
to the pathogen causing the pneumonia: IPA group, PCP group, and
‘others’ group. The ‘others’ group included patients with pneumo-
nia caused by pathogens other than Aspergillus and P.
jirovecii. Fifty pediatric oncology patients who underwent Th1/
Th2 cytokine measurement at admission and who were without
symptoms or signs of infection served as a control group.
Information including patient demographic characteristics and
clinical and laboratory ﬁndings at diagnosis was collected for
analysis in this study.
2.2. Deﬁnition of IPA and PCP
The diagnosis of IPA was obtained when the following criteria
were fulﬁlled: (1) host factors such as neutropenia, corticosteroid
or immunosuppressant use, or chemotherapy; (2) clinical symp-
toms including cough, respiratory distress, dyspnea, and fever
resistant to antibiotics for more than 72 h; (3) pulmonary
computed tomography (CT) scan showing typical signs, such as
nodular lesions with or without halo, cavities, and air crescent
sign; (4) positive result for serum galactomannan (GM) antigen,
direct stain, or culture as mycological evidence of IPA; (5) empirical
therapy and deﬁnitive therapy with one or a combination of
antifungal drugs was effective.13
The clinical diagnosis of PCP was retained when (1) at least two
of the three following signs were present: non-productive cough or
cough producing clear sputum, fever, and dyspnea increasing over
time; (2) chest X-ray revealed the characteristic diffuse inﬁltra-
tions in both lung ﬁelds, or a chest high-resolution CT scan showedTable 1
Comparisons of demographic characteristics and laboratory ﬁndings between patients
Characteristics IPA PC
Sex, male/female 66/49 24
Age, years, median (range) 7.3 (0.9–15.4) 5
Underlying disease 
ALL 99 (86.1%) 32
AML 14 (12.2%) 3
Neutropenia 81 (70.4%) 13
Oxygen support 18 (15.6%) 22
Death 2 (1.7%) 2
IL-2 (pg/ml) 2.9 (1.0–5.7) 2
IL-4 (pg/ml) 3.0 (1.0–91.0) 3
IL-6 (pg/ml) 52.0 (2.5–2484.0) 25
IL-10 (pg/ml) 6.7 (1.0–147.0) 7
TNF-a (pg/ml) 2.1 (1.0–63.0) 2
IFN-g (pg/ml) 8.9 (1.0–1100.6) 19
CRP (mg/l) 52 (1–200) 34
PCT (mg/l) 0.22 (0.02–48.7) 0
IPA, invasive pulmonary aspergillosis; PCP, Pneumocystis pneumonia; ALL, acute lympho
factor; IFN, interferon; CRP, C-reactive protein; PCT, procalcitonin.
a Comparison between IPA and PCP groups.diffuse frosted glass opacities and thickened alveolar sputum in
both lungs; (3) a favorable outcome was obtained under co-
trimoxazole therapy, provided that no other infectious agent was
found.14
2.3. Th1/Th2 cytokine measurement
The Th1/Th2 cytokines were measured at diagnosis. Concen-
trations of IFN-g, TNF-a, IL-10, IL-6, IL-4, and IL-2 were determined
quantitatively using a cytometric bead array (CBA) kit (CBA Human
Th1/Th2 Cytokine Kit II; BD Biosciences, San Jose, CA, USA), as
described previously.15
2.4. Statistical analysis
Comparisons were performed using the Chi-square test or
Fisher’s exact test for categorical variables, and using the Mann–
Whitney U-test (for two groups) or Kruskal–Wallis H-test (for
three groups) for continuous variables. Receiver operating
characteristic (ROC) curves were used to evaluate the discrimina-
tory power (represented by the area under the curve) of IL-6, IFN-g,
and their ratios to differentiate IPA and PCP and to determine the
cut-off values with optimal sensitivity and speciﬁcity. All
statistical analyses were performed using IBM SPSS Statistics
version 20.0 software (IBM Corp., Armonk, NY, USA). A p-value of
<0.05 was considered to be statistically signiﬁcant.
3. Results
3.1. Patient characteristics
A total of 277 pediatric oncology patients (227 patients with
acute pneumonia and 50 control cases) were included in this
retrospective analysis: 115 patients had IPA, 37 had PCP, 75 had
pneumonia caused by other pathogens (50 by Mycoplasma
pneumoniae, 15 by bacteria, and 10 by viruses and others), and
50 were control cases without symptoms or signs of infection. The
demographic characteristics of the IPA, PCP, and other pneumonia
groups are shown in Table 1. The age and sex distribution were
comparable between the IPA and PCP groups. Acute lymphoblastic
leukemia and acute myeloid leukemia were the major underlying
diseases in this cohort. More than 70% of patients with IPA were in
a neutropenic state when the diagnosis was made, while only
about one-third of patients with PCP were neutropenic. On the
other hand, more patients with PCP needed oxygen support with IPA and PCP
P Other pneumonia p-Valuea
/13 45/30 0.421
.3 (1.3–15.9) 4.0 (1.0–12.3) 0.072
0.763
 (86.5%) 53 (70.7%)
 (8.1%) 11 (14.7%)
 (38.2%) 7 (9.3%) <0.001
 (59.5%) 5 (6.7%) <0.001
 (5.4%) 0 (0%) 0.084
.7 (1.0–6.0) 3.2 (1.0–7.1) 0.954
.0 (1.0–80.0) 3.3 (1.2–30.0) 0.507
.8 (4.6–3738.1) 13.7 (1.3–552.9) 0.092
.7 (2.2–117.4) 4.9 (1.7–61.2) 0.701
.2 (1.0–52.3) 2.2 (1.0–48.0) 0.870
.9 (2.0–186.0) 10.2 (1.2–164.7) 0.001
 (1–165) 7.0 (1–161) 0.827
.19 (0.06–8.7) 0.11 (0.02–2.59) 0.903
blastic leukemia; AML, acute myeloid leukemia; IL, interleukin; TNF, tumor necrosis
Table 2
Predictive accuracy of IL-6 and IFN-g for PCP and IPA
Cut-off Target Sensitivity Speciﬁcity
IL-6 17.5 pg/ml IPA 80.0% (71.8–86.3) 48.2% (39.2–57.4)
52.0 pg/ml IPA 50.4% (41.4–59.4) 77.7% (69.1–84.4)
140 pg/ml IPA 21.7% (15.2–30.1) 88.4% (81.1–93.1)
IFN-g 6.5 pg/ml PCP 81.1% (65.8–90.5) 30.0% (23.9–36.9)
24.0 pg/ml PCP 51.4% (35.9–66.6) 82.6% (76.6–87.6)
40.0 pg/ml PCP 35.1% (21.8–51.2) 89.5% (84.3–93.1)
IL-6/IFN-g 1.0 IPA 80.9% (72.7–87.0) 40.2% (31.6–49.4)
3.4 IPA 59.1% (50.0–67.7) 78.6% (70.1–85.2)
9.0 IPA 36.5% (28.3–45.6) 91.1% (84.3–95.1)
IFN-g/IL-6a 0.25 PCP 83.8% (68.9–92.4) 59.1% (50.0–67.7)
0.43 PCP 43.2% (28.7–59.1) 80.0% (71.7–86.3)
1.6 PCP 35.1% (21.8–51.2) 89.6% (82.6–93.9)
IL, interleukin; IFN, interferon; PCP, Pneumocystis pneumonia; IPA, invasive
pulmonary aspergillosis.
a Includes only IPA and PCP groups.
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mechanical ventilation) than patients with IPA (14 with nasal
cannula and four with a mask). Four patients died of pulmonary
infection. The death rate was comparable between the two groups.
3.2. Th1/Th2 cytokines in patients with IPA and PCP
The distribution of Th1/Th2 cytokines at the time of diagnosis is
shown in Figure 1 and Table 1. The normal median and range
values were as follows: IL-2, 2.9 (1.0–4.8) pg/ml; IL-4, 3.0 (1.2–5.1)
pg/ml, IL-6, 5.6 (2.3–8.6) pg/ml, IL-10, 7.5 (2.9–13.7) pg/ml, TNF-a,
3.8 (1.7–9.7) pg/ml, and IFN-g, 5.5 (2.0–9.2) pg/ml. Of the six
cytokines, IL-2, IL-4, IL-10, and TNF-a values were comparable
among patients with IPA, PCP, other pneumonia, and control cases,
while IL-6 and IFN-g levels were elevated in patients with IPA, PCP,
and other pneumonia when compared with control cases
(Figure 1). The IL-6 concentration in patients with IPA was
signiﬁcantly higher than that in patients with other pneumonia
(p < 0.001), and appeared to be higher than that in patients with
PCP, but without statistical signiﬁcance (p = 0.092). The IFN-g
concentration was much higher in patients with PCP compared
with patients with IPA (p = 0.001) or other pneumonia (p = 0.011).
C-reactive protein (CRP) was moderately elevated in most patients
with IPA and PCP, and was both higher than that in patients with
other pneumonia (both p < 0.001) . A similar trend was found for
procalcitonin (PCT), although the PCT level was within the normal
range in most patients. Both CRP and PCT were comparable
between patients with IPA and PCP.
3.3. Differentiating IPA from PCP by IL-6 and IFN-g
As IL-6 and IFN-g were elevated in patients with acute
pneumonia, their role in predicting IPA and PCP was then
investigated. As shown in Figure 2, the diagnostic accuracy of
IL-6 and IFN-g in predicting IPA and PCP was 69.0% (95%Figure 1. Distribution of IL-6, IFN-g and IL-6 to IFN-g ratio in control and patients with acu
Figure 2. Accuracy of IL-6 (A) and IL-6 to IFN-g ratio (B) to predict IPA and IFN-g to preconﬁdence interval (CI) 62.1–76.0%) and 67.2% (95% CI 56.9–
77.5%), respectively. Next, whether the ratio of IL-6 to IFN-g
performed better than either one parameter was investigated. As
shown in Figures 1 and 2, the median and range IL-6/IFN-g ratio
was 4.9 (0.02–776.3) in patients with IPA, 1.6 (0.09–189.7) in
patients with PCP, and 1.33 (0.09–32.5) in patients with other
pneumonia. The diagnostic accuracy of the IL-6/IFN-g ratio in
predicting IPA was 72.0% (95% CI 65.4–78.7%). Based on the ROC
analysis, as shown in Table 2, an IL-6 concentration higher than
52 pg/ml and an IFN-g concentration higher than 24 pg/ml yielded
a sensitivity of about 50% and a speciﬁcity of about 80% when
predicting IPA and PCP, respectively. When the cut-off value of IL-6
was set at 140 pg/ml and the cut-off value of IFN-g was set at 40 pg/
ml, the speciﬁcities could reach as high as nearly 90%. The IL-6/IFN-
g ratio presented higher accuracy to predict IPA when compared
with IL-6, yielding a sensitivity of 59.1% and a speciﬁcity of 78.6% atte pneumonias. IPA, invasive pulmonary aspergillosis; PCP, Pneumocystis pneumonia.
dict PCP (C). IPA, invasive pulmonary aspergillosis; PCP, Pneumocystis pneumonia.
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speciﬁcity could be higher than 90%. In contrast, among patients
with IPA and PCP, if the IFN-g/IL-6 ratio was higher than 1.6 (IL-6/
IFN-g ratio less than 0.63), the speciﬁcity to diagnose PCP could be
nearly 90%.
4. Discussion
IPA and PCP are two types of potentially life-threatening fungal
infection seen predominantly in immunocompromised individua-
ls. Despite progress in understanding these diseases and the
availability of new fungicidal agents, the mortality rates in
pediatric hematology–oncology patients remain high. This is in
part related to the difﬁculty in making a sensitive and speciﬁc
diagnosis. Delayed diagnosis has an obvious impact on the
initiation of early treatment and consequently on the patient’s
prognosis.16 For example, although a deﬁnite PCP diagnosis can be
made when the P. jirovecii organism is found in respiratory samples
using light microscopy, immunoﬂuorescence, or molecular meth-
ods, obtaining the samples necessary for these techniques from
pediatric hematology–oncology patients, including bronchoalveo-
lar lavage ﬂuid, induced sputum, and biopsies, is really difﬁcult.
The serum b-1,3-glucan level is a marker of Pneumocystis
infection that can contribute to the diagnosis of PCP;17,18 however,
it takes a long time for results to become available and it is not
helpful to differentiate various fungal infections. The serum
galactomannan assay is reported to be sensitive and speciﬁc for
the diagnosis of invasive aspergillosis.19 However, it appears to be
insufﬁciently sensitive when performed in many Chinese institu-
tions due to reagents or problems with the technique.
During Aspergillus infection, monocytes, macrophages, and
neutrophils mostly contribute to the antifungal innate immune
response through phagocytosis and direct pathogen killing. Then,
the development of speciﬁc T-helper cell (Th) responses is
protective against the development of IPA.20,21 The Th1 response
is associated with an increased production of inﬂammatory
cytokines such as IFN-g, IL-6, and IL-12 and the stimulation of
antifungal effector cells.22,23 IFN-g is a highly potent activator of
phagocytes against opportunistic fungal pathogens in humans. IL-
6 appears to have a protective proinﬂammatory and immuno-
modulatory role in pulmonary host defense.
For Pneumocystis infection, alveolar macrophages are the
primary resident phagocytes that mediate clearance of Pneumo-
cystis from the lung, which release TNF, IL-1, and IL-6.24 These
cytokines initiate the CD4+ T-cell response during PCP. CD4+ T-
cells proliferate in response to Pneumocystis antigens and
generate IFN-g, which augments the Pneumocystis-associated
host response. However, different from IPA, PCP is an immunor-
estitution disease that symptomatically or paradoxically deterio-
rates during recovery of the immune system .9 This indicates that
immunopathological damage contributes to the development of
this disease, especially during the reversal of the immunosuppres-
sive processes. The overwhelming T-cell activation contributes to
the predominant level of IFN-g. The ﬁnding in the present study
that about two-thirds of patients with PCP were not in a
neutropenic state is consistent with this theory.
IPA and PCP share many similar features, which leads to
difﬁculty in differentiating the two entities; these include similar
clinical manifestations and radiological imaging. Furthermore, as
many laboratory tests are not speciﬁc or not easily available, it is a
great challenge for clinicians to make a quick diagnosis based on
the limited evidence. The role of serum inﬂammatory markers such
as CRP, PCT, and IL-6 in the diagnosis of fungal infection has been
evaluated in a few retrospective studies; however, these studies
have generated heterogeneous ﬁndings.25–27 In this study, the role
of inﬂammatory cytokines in the diagnosis of pulmonary fungalinfection was investigated and it was found that IL-6 and IFN-g are
frequently elevated in patients with IPA and PCP. However, the two
entities present different cytokine proﬁles. IL-6 is predominantly
increased in patients with IPA, while IFN-g is more signiﬁcantly
increased in patients with PCP. As the two markers do not increase
in parallel in these two diseases, the ratio of IL-6/IFN-g is an even
more accurate marker to differentiate IPA and PCP. When the ratio
is higher than 9.0 or less than 0.63, the speciﬁcities to diagnose IPA
and PCP can reach as high as 90%. This appears to be the ﬁrst report
on the role of IL-6 and IFN-g in diagnosing fungal infection. The
results of Th1/Th2 cytokine measurements can be obtained within
5 h of sample collection when using CBA technology, which makes
this a helpful approach for the rapid diagnosis of critical diseases
like IPA and PCP.
There are some limitations to this study. Histopathological
results were lacking for most of the patients in this cohort diagnosed
with IPA and PCP. Therefore, the possibility that some of the patients
had another type of fungal infection, such as candidiasis, cannot be
excluded. Also, this was a retrospective study and the cytokine
results that were used were those measured at the time the fungal
infection was suspected; the cytokines were not dynamically
monitored thereafter, thus the concentrations of cytokines mea-
sured may not be the peak levels and they may not have been
obtained at the same stage of disease. This may lead to heterogeneity
or bias.
In conclusion, IL-6 and IFN-g are increased in the serum of
patients with IPA and PCP. IL-6 is predominantly elevated in IPA,
while IFN-g is signiﬁcantly increased in PCP. Thus, the concentra-
tions of IL-6 and IFN-g and the ratio of IL-6/IFN-g are helpful for the
differential diagnosis of IPA and PCP.
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